Poongjeon Pharmacy
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Poongjeon Pharmacy is a Korean company listed on KOSDAQ that operates across three business lines: developing stem-cell therapies for rare diseases, making and distributing hair-care and skin-care cosmetics under its Iroro and Dermassimo brands, and wholesaling prescription medicines to large hospitals.
Its cosmetics reach consumers through its own online stores, home-shopping channels, and export partners in Malaysia and Japan. The business is structured around three distinct divisions, with the pharmaceutical wholesale arm added through a merger.
Summary is AI-generated and may contain errors · figures from DART filings
The company absorbed Dermassimo brand owner by merger and has a further planned merger with pharmaceutical wholesaler Pungjeon Pharmaceutical Co., Ltd. to add the medicines distribution division.
Poongjeon Pharmacy in five facts
What does Poongjeon Pharmacy do?
Poongjeon Pharmacy is a Korean company listed on KOSDAQ that operates across three business lines: developing stem-cell therapies for rare diseases, making and distributing hair-care and skin-care cosmetics under its Iroro and Dermassimo brands, and wholesaling prescription medicines to large hospitals.
Where is Poongjeon Pharmacy listed and in which sector?
Poongjeon Pharmacy (Korean name: 풍전약품) trades under KRX code 298060 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Poongjeon Pharmacy?
Its market capitalisation was US$16M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Poongjeon Pharmacy's latest annual revenue and operating profit?
For fiscal year 2025, Poongjeon Pharmacy reported revenue of US$18M, an operating loss of US$3.4M and net income of US$152.8K, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 2790.3% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Results of extraordinary shareholders' meetingSep 30
- Report on large shareholdings (5% rule) (abbreviated)Sep 30
- [Amended] Resolution to convene a general shareholders' meeting (extraordinary meeting)Sep 15
- Notice of general shareholders' meetingSep 15
- Material event report (convertible bonds)
Poongjeon Pharmacy disclosed convertible bonds to raise US$1.31M, about 8.8% of its market value.
Capital raise · Jun 10 - Material event report (rights offering)
Poongjeon Pharmacy disclosed a private placement (third-party allotment) to raise US$1.31M, about 8.8% of its market value.
Capital raise · Jun 10 - Trading suspension (share consolidation/split registration)M&A · Apr 20
- Completion report on merger, etc. (merger)M&A · Apr 1
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Poongjeon Pharmacy reported consolidated results for FY2025: revenue of US$16.5M (+2795.6% year on year), an operating loss of US$3.11M and a net loss of US$315K.
Earnings · Feb 23 - [Attachment amended] Material event report (merger)M&A · Jan 15
- [Attachment amended] Material event report (merger)M&A · Jan 14
- Material event report (merger)M&A · Jan 14